Announcements Trials
Browse Landscape

Phase

Phase 2 54Phase 3 24Phase 2/3 5Phase 4 4Phase 1/2 4Phase NA 2Phase 1 2

Status

Completed 15Unknown 14Recruiting 8Active not recruiting 7Withdrawn 5Not yet recruiting 5Terminated 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2HER2-positive Gastric Cancer 1

Interventions

Cisplatin 10Gemcitabine 7Fluorouracil 7Carboplatin 7Capecitabine 7venetoclax 5Oxaliplatin 5Cyclophosphamide 4sintilimab 3Radiotherapy 3Neoadjuvant Therapy 3Dexamethasone 3Bevacizumab 3Azacitidine 3130-nm albumin-bound paclitaxel 3trametinib 2regorafenib 2pembrolizumab 2nimotuzumab 2fludarabine 2disitamab vedotin 2daratumumab 2dabrafenib 2camrelizumab 2blinatumomab 2apatinib 2Trastuzumab 2Temozolomide 2Radiotherapy, Intensity-Modulated 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × Oxaliplatin × Clear all
NCT07437287 2026-02-27

CROCOBIL

UNICANCER

Phase 2/3 Not yet recruiting
160 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07392866 2026-02-09

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 2/3 Not yet recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Sun Yat-sen University

Phase 2/3 Not yet recruiting
206 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
668 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡